This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-Hodgkin's lymphoma (NHL)	Tumor necrosis factor- α -induced protein 3 (TNFAIP3; A20)	Studies in patient samples and in cell culture suggest that enhancing the activity of A20 could help treat NHL. In an analysis of NHL patients, 22% of the samples contained cells with a deletion in A20. In cultured lymphoma cells lacking A20, lentiviral-mediated expression of wild-type A20 increased apoptosis compared with expression of a control vector. Next steps include evaluating tumor development in $A20^{+/-}$ mice and in conditional knockout mice lacking A20 in B cells.	Work unpatented; licensing status not applicable	Honma, K. <i>et al. Blood</i> ; published online July 16, 2009; doi:10.1182/blood-2008-12-194852 Contact: Masao Seto, Aichi Cancer Center Hospital, Nagoya, Japan e-mail: mseto@aichi-cc.jp
<i>SciBX</i> 2(29); doi:10.1038/scibx.2009.1145 Published online July 30, 2009				